Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Overexpression”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07662473
What this trial is testing

The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 30
Not applicableStudy completedNCT05902494
What this trial is testing

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 389
Not applicableEnded earlyNCT02840110
What this trial is testing

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Who this might be right for
B Cell LymphomasMultiple MyelomaSolid Tumor+1 more
Cogent Biosciences, Inc. 22
Testing effectiveness (Phase 2)Study completedNCT00023998
What this trial is testing

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Who this might be right for
Metastatic Osteosarcoma
National Cancer Institute (NCI) 80
Early research (Phase 1)Ended earlyNCT03680560
What this trial is testing

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Who this might be right for
Solid TumorHER-2 Protein Overexpression
Cogent Biosciences, Inc. 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT06187506
What this trial is testing

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder CancerHER-2 Protein Overexpression
Fudan University 20
Early research (Phase 1)Study completedNCT00009997
What this trial is testing

Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
NYU Langone Health
Testing effectiveness (Phase 2)Study completedNCT00003995
What this trial is testing

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

Who this might be right for
Colorectal Cancer
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)UnknownNCT00003797
What this trial is testing

Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas

Who this might be right for
Pancreatic Cancer
Brown University 41
Early research (Phase 1)Temporarily pausedNCT04650451
What this trial is testing

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Who this might be right for
HER-2 Gene AmplificationHER2-positive Gastric CancerHER2-positive Breast Cancer+2 more
Bellicum Pharmaceuticals 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384
What this trial is testing

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Who this might be right for
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Brown University 1
Early research (Phase 1)Study completedNCT03255070
What this trial is testing

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Who this might be right for
Breast NeoplasmsGastric NeoplasmSolid Tumors
Ambrx, Inc. 106
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06385873
What this trial is testing

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 32
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Testing effectiveness (Phase 2)Study completedNCT00193089
What this trial is testing

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 60
Early research (Phase 1)Study completedNCT00906698
What this trial is testing

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Who this might be right for
Neoplasms
Boehringer Ingelheim 55
Early research (Phase 1)Active Not RecruitingNCT06328738
What this trial is testing

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2 Positive Solid Tumors+2 more
Enliven Therapeutics 275
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Not applicableNot Yet RecruitingNCT07035353
What this trial is testing

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Who this might be right for
HER2 OverexpressionAdvanced Stage Breast CancerLow Expression of HER2
Tianjin Medical University Cancer Institute and Hospital 200
Next Page